Industry News

Pharmaceutical Industry News

Biogen recorded declining sales…

February 6th, 2026|Fierce Pharma|

Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees positive signs with the recent launch of its high-dose version of the spinal muscular atrophy treatment

The stock price of BridgeBio…

February 6th, 2026|Fierce Pharma|

The stock price of BridgeBio plunged 15% Thursday on Pfizer's reported decision to withdraw a tafamidis patent in the EU, triggering fears of earlier generic entry in the blockbuster ATTR-CM market.

“FDA will take swift action…

February 6th, 2026|Fierce Pharma|

“FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products,” FDA commissioner Marty Makary, M.D., said in a Feb. 5 post on X. The comments mark a

On this week’s “The Top Line,”…

February 5th, 2026|Fierce Pharma|

On this week’s "The Top Line," Fierce’s Andrea Park and Gabrielle Masson dive into the most anticipated drug launches of 2026 and the blockbuster sales potential shaping biopharma’s next wave.

Amgen added to uncertainty…

February 5th, 2026|Fierce Pharma|

Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. Roche penned a deal worth up to $1.7 billion for an RNA interference program from SanegeneBio. Daiichi Sankyo

Thursday evening, President Donald…

February 5th, 2026|Fierce Pharma|

Thursday evening, President Donald Trump debuted TrumpRx, a government-run website that directs patients toward cash-pay channels where they can purchase certain prescription drugs.

A month after drugmaker Novo…

February 5th, 2026|Fierce Pharma|

A month after drugmaker Novo Nordisk launched its Wegovy pill, online health and wellness company Hims & Hers plans to undercut it with a compounded semaglutide pill offered at a lower price.

The majority of Bristol Myers…

February 5th, 2026|Fierce Pharma|

The majority of Bristol Myers Squibb's $48.2 billion revenue haul in 2025 came from its collection of newer growth products as its legacy portfolio declines.

Astellas surpassed market…

February 5th, 2026|Fierce Pharma|

Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales.

In its initial public offering,…

February 5th, 2026|Fierce Pharma|

In its initial public offering, Veradermics sold a little over 15 million shares of common stock at $17 apiece, raising a total of $256.3 million in its entry onto the New York Stock Exchange, according

Merz Therapeutics has launched a…

February 5th, 2026|Fierce Pharma|

Merz Therapeutics has launched a punchy marketing campaign for Parkinson’s disease drug Inbrija, working Muhammad Ali quotes and footage into a revised version of the med’s “For the Fighters” initiative.

By signing a government funding…

February 4th, 2026|Fierce Pharma|

By signing a government funding bill that ended a partial shutdown, President Donald Trump has also reauthorized a beloved program meant to speed the development of new drugs for rare childhood diseases.